At 6.8% CAGR, Middle East & Africa Hyperpigmentation Disorder Treatment Market is Projected to be Worth US$ 894.55 Million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa hyperpigmentation disorder treatment market was valued at US$ 530.30 million in 2022 and is expected to reach US$ 894.55 million by 2030, registering a CAGR of 6.8% from 2022 to 2030. Increasing number of hyperpigmentation disorder awareness programs and rise in prevalence of melasma are among the critical factors attributed to drive the Middle East & Africa hyperpigmentation disorder treatment market growth.

Melasma, one of the most dominant hyperpigmentation conditions, is characterized by symmetrical light to dark muddy-brown macules with borders on the face, particularly the chin, upper lip, nose, forehead, and cheeks. It is prevalent among women and those with darker complexion. Malar, mandibular, and centrofacial clinical features are common in melasma. Sun exposure, hormonal variations, pregnancy, hereditary factors, cosmetics, and medicines have all been linked to the development of melasma. Various studies have estimated that the overall prevalence of melasma in the general population ranges from 1% to 50%. 55–64% of melasma cases have reported a family history of the same condition. Pregnancy is another common cause of melasma. This condition also impacts women taking oral contraceptives and hormones. Estrogen, progesterone, and melanocyte-stimulating hormone levels normally rise during the third trimester of pregnancy, which may be a factor. According to the National Center for Biotechnology Information (NCBI) in August 2023, melasma is more common in reproductive years, and it rarely occurs before puberty; the condition occurs in 15–50% of pregnant women, and its prevalence ranges from 1.5% to 33%, depending on the population in a different region. Therefore, an upsurge in melasma prevalence triggers the demand for hyperpigmentation treatments.

On the contrary, high cost of treatments hampers the growth of Middle East & Africa hyperpigmentation disorder treatment market.

By treatment type, the Middle East & Africa hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held 42.3% share of Middle East & Africa hyperpigmentation disorder treatment market share in 2022, amassing US$ 224.26 million. It is projected to garner US$ 392.12 million by 2030 to register 7.2% CAGR during 2022–2030.

In terms of condition, the Middle East & Africa hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held 47.4% share of Middle East & Africa hyperpigmentation disorder treatment market share in 2022, amassing US$ 251.46 million. It is projected to garner US$ 435.39 million by 2030 to register 7.1% CAGR during 2022–2030.

Based on end user, the Middle East & Africa hyperpigmentation disorder treatment market is hospitals, dermatology centers, and others. The hospital segment held 47.8% share of Middle East & Africa hyperpigmentation disorder treatment market share in 2022, amassing US$ 253.38 million. It is projected to garner US$ 424.61 million by 2030 to register 6.7% CAGR during 2022–2030.

Based on country, the Middle East & Africa hyperpigmentation disorder treatment market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 28.3% share of Middle East & Africa hyperpigmentation disorder treatment market in 2022. It was assessed at US$ 150.18 million in 2022 and is likely to hit US$ 236.35 million by 2030, registering a CAGR of 5.8% during 2022–2030.

Key players operating in the Middle East & Africa hyperpigmentation disorder treatment market are AbbVie Inc, Bayer AG, Galderma SA, L’OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Pierre Fabre SA, among others.

• In February 2024: L'Oréal Paris launched the Glycolic Bright Dark Circle Eye Serum, a groundbreaking solution for under-eye hyperpigmentation and puffiness. The serum, formulated with a blend of 3 percent Glycolic Acid, Vitamin CG, and Niacinamide, promises to diminish dark circles by -49% in just two weeks. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com